Mutations in TREM2 lead to pure early-onset dementia without bone cysts
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
A genome-wide screen using 382 STR markers to localize and identify the gene implicated in early-onset dementia (EOD) without bone cysts in a Lebanese family with three affected subjects was conducted. A unique locus homozygous by descent at chromosome 6p21.2 locus was identified. Candidate genes were explored by fluorescent sequencing and the effect of the identified mutation was confirmed by qualitative and quantitative RT-PCR. The genetic analysis revealed a novel deletion, c.40+3delAGG, in the 5' consensus donor splice site in intron 1 of TREM2 gene which is known to be responsible for PLOSL (Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy) also designated as Nasu-Hakola disease. In silico analysis predicted a lower strength for the novel donor splice site. Qualitative RT-PCR revealed normal transcript while quantitative RT-PCR showed over twofold down-regulation of TREM2 transcripts. The expression profile of six genes SPP1, NEDD9, FSCN, BCL3, NFKBIA and CCL2 known as disrupted in TREM2-deficient samples was studied and showed same expression profile as TREM2-mutated samples except for CCL2 which was normally regulated. The significantly-reduced expression of TREM2 in our patients and the expression profiles of the six studied genes confirm a role for TREM2 in this distinct phenotype of EOD without bone cysts. To our knowledge, this is the first report of mutations in TREM2 causing a pure dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Listening to silence and understanding nonsense: exonic mutations that affect splicing
Cartegni, L., Chew, S. L., & Krainer, A. R. (2002) · Nature Reviews Genetics · doi:10.1038/nrg775 · Cited by 2,209 · cited 1×
“This mutation likely causes aberrant splicing because it occurs within the U1 snRNP recognition sequence and replaces the conserved guanine [Cartegni et al., 2002] at the position +5 with a cytosine.”
BackgroundPaloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R., Salmaggi, A., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342259 · Cited by 683 · cited 1×
“DAP12 named also TYROBP (TYRO protein tyrosine kinase binding protein; MIM# 604142) and TREM2 (triggering receptors expressed on myeloid cells-2; MIM# 605086) are responsible for PLOSL (Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy; MIM# 221770), an autosomal recessive disease characteri…”
BackgroundVariation in alternative splicing across human tissues
Yeo, G., Holste, D., Kreiman, G., & Burge, C. B. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r74 · Cited by 584 · cited 1×
“On the other hand, it has been already shown that human brain, testis and liver have an unusually high levels of alternative pre-mRNA splicing [Yeo et al., 2004].”
BackgroundLoss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts
Paloneva, J., Kestilä, M., Wu, J., Salminen, A., Böhling, T., Ruotsalainen, V., Hakola, P., Bakker, A. B. H., Phillips, J. H., Pekkarinen, P., et al. (2000) · Nature Genetics · doi:10.1038/77153 · Cited by 460 · cited 1×
“DAP12 named also TYROBP (TYRO protein tyrosine kinase binding protein; MIM# 604142) and TREM2 (triggering receptors expressed on myeloid cells-2; MIM# 605086) are responsible for PLOSL (Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy; MIM# 221770), an autosomal recessive disease characteri…”
BackgroundThe genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2
Klünemann, H. H., Ridha, B. H., Magy, L., Wherrett, J. R., Hemelsoet, D. M., Keen, R. W., De Bleecker, J. L., Rossor, M. N., Marienhagen, J., Klein, H. E., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000160304.00003.ca · Cited by 254 · cited 1×
“DAP12 named also TYROBP (TYRO protein tyrosine kinase binding protein; MIM# 604142) and TREM2 (triggering receptors expressed on myeloid cells-2; MIM# 605086) are responsible for PLOSL (Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy; MIM# 221770), an autosomal recessive disease characteri…”
BackgroundNeumann, H., & Takahashi, K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.032 · Cited by 249
The Genetics of Very Early Onset Alzheimer Disease
Filley, C. M., Rollins, Y. D., Alan Anderson, C., Arciniegas, D. B., Howard, K. L., Murrell, J. R., Boyer, P. J., Kleinschmidt-DeMasters, B. K., & Ghetti, B. (2007) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0b013e318145a8c8 · Cited by 53 · cited 1×
“PSEN1 (presenilin 1), PSEN2 (presenilin 2) and APP (amyloid precursor protein) are implicated in early onset AD [Filley et al., 2007].”
Background
Cited by
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
The myeloid cells of the central nervous system parenchyma
Ransohoff, R. M., & Cardona, A. E. (2010) · Nature · doi:10.1038/nature09615 · Cited by 804
Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response
Bachiller, S., Jiménez-Ferrer, I., Paulus, A., Yang, Y., Swanberg, M., Deierborg, T., & Boza-Serrano, A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00488 · Cited by 707
Rademakers, R., Baker, M., Nicholson, A. M., Rutherford, N. J., Finch, N., Soto-Ortolaza, A., Lash, J., Wider, C., Wojtas, A., DeJesus-Hernandez, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.1027 · Cited by 571
TREM2, microglia, and neurodegenerative diseases
Yeh, F. L., Hansen, D. V., & Sheng, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.008 · Cited by 440
TREM2 in Neurodegenerative Diseases
Jay, T. R., von Saucken, V. E., & Landreth, G. E. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0197-5 · Cited by 427
Rayaprolu, S., Mullen, B., Baker, M., Lynch, T., Finger, E., Seeley, W. W., Hatanpaa, K. J., Lomen-Hoerth, C., Kertesz, A., Bigio, E. H., et al. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-19 · Cited by 404
Colonna, M. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00837-1 · Cited by 394
Guerreiro, R. J., Lohmann, E., Brás, J. M., Gibbs, J. R., Rohrer, J. D., Gurunlian, N., Dursun, B., Bilgic, B., Hanagasi, H., Gurvit, H., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.579 · Cited by 374
Loy, C. T., Schofield, P. R., Turner, A. M., & Kwok, J. B. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60630-3 · Cited by 342
Immune Signaling in Neurodegeneration
Hammond, T. R., Marsh, S. E., & Stevens, B. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.016 · Cited by 336
“In addition, homozygous TREM2 variants were also found to be potentially casual for a form of FTD (Carmona et al., 2018; Chouery et al., 2008; Guerreiro et al., 2013a), while other variants significantly elevated FTD risk (Carmona et al.”
BackgroundCoding variants in TREM2 increase risk for Alzheimer's disease
Jin, S. C., Benitez, B. A., Karch, C. M., Cooper, B., Skorupa, T., Carrell, D., Norton, J. B., Hsu, S., Harari, O., Cai, Y., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu277 · Cited by 314
The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E
Bailey, C. C., DeVaux, L. B., & Farzan, M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.677286 · Cited by 303
Bemiller, S. M., McCray, T. J., Allan, K., Formica, S. V., Xu, G., Wilson, G., Kokiko-Cochran, O. N., Crish, S. D., Lasagna-Reeves, C. A., Ransohoff, R. M., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0216-6 · Cited by 299
Functional differences between microglia and monocytes after ischemic stroke
Ritzel, R. M., Patel, A. R., Grenier, J. M., Crapser, J., Verma, R., Jellison, E. R., & McCullough, L. D. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0329-1 · Cited by 295
“be non-deleterious in the short-term, the long-term consequences of microglia removal are likely detrimental to CNS homeostasis as evidenced in several neurodegenerative models [34–37].”
BackgroundTREM2-Ligand Interactions in Health and Disease
Kober, D. L., & Brett, T. J. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.04.004 · Cited by 284
“The TREM2 variants include splice site [7, 9] early stop sites [7, 10–12], and coding ectodomain mutations [7, 8, 13–15].”
BackgroundThe role of TREM2 in Alzheimer's disease and other neurodegenerative disorders
Carmona, S., Zahs, K., Wu, E., Dakin, K., Bras, J., & Guerreiro, R. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30232-1 · Cited by 244
Oosterhof, N., Chang, I. J., Karimiani, E. G., Kuil, L. E., Jensen, D. M., Daza, R., Young, E., Astle, L., van der Linde, H. C., Shivaram, G. M., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.03.010 · Cited by 247
Kober, D. L., Alexander-Brett, J. M., Karch, C. M., Cruchaga, C., Colonna, M., Holtzman, M. J., & Brett, T. J. (2016) · eLife · doi:10.7554/elife.20391 · Cited by 238
Functional Studies of Missense TREM2 Mutations in Human Stem Cell-Derived Microglia
Brownjohn, P. W., Smith, J., Solanki, R., Lohmann, E., Houlden, H., Hardy, J., Dietmann, S., & Livesey, F. J. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.03.003 · Cited by 193
“…with bone cysts and an early-onset dementia (Paloneva et al., 2000, 2002), while a frontotemporal dementia (FTD)-like syndrome without bone dysfunction has also been described in patients carrying certain TREM2 mutations (Chouery et al., 2008; Giraldo et al., 2013; Guerreiro et al., 2013b).”
BackgroundCAS proteins in normal and pathological cell growth control
Tikhmyanova, N., Little, J. L., & Golemis, E. A. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0213-1 · Cited by 187
“Intriguingly, a TREM2 loss-of-function mutation linked with dementia may lead to significant downregulation of NEDD9 mRNA [247].”
TREM2 is associated with the risk of Alzheimer's disease in Spanish population
Benitez, B. A., Cooper, B., Pastor, P., Jin, S.-C., Lorenzo, E., Cervantes, S., & Cruchaga, C. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.018 · Cited by 163
“Cruchaga). ll rights reserved. symptoms (bone cysts) (Chouery et al., 2008).”
Garcia-Reitboeck, P., Phillips, A., Piers, T. M., Villegas-Llerena, C., Butler, M., Mallach, A., Rodrigues, C., Arber, C. E., Heslegrave, A., Zetterberg, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.094 · Cited by 162
“TREM2 mRNA levels were previously found to be reduced in patients with NHD caused by TREM2 variants (Chouery et al., 2008; Sasaki et al., 2015), and we found this to be the case for T66Mhom andW50Chom but not for T66Mhet iPSC-MGLCs.”
BackgroundGuerreiro, R., Bilgic, B., Guven, G., Brás, J., Rohrer, J., Lohmann, E., Hanagasi, H., Gurvit, H., & Emre, M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.005 · Cited by 158
“…cases with homozygous mutations in TREM2 have been described to present atypical phenotypes resembling behavioral variant frontotemporal dementia (bvFTD) and lacking stage (2) of the clinical picture described previously (Chouery et al., 2008; Giraldo et al., 2013; Guerreiro et al., 2013b).”
BackgroundInfluentialGiraldo, M., Lopera, F., Siniard, A. L., Corneveaux, J. J., Schrauwen, I., Carvajal, J., Muñoz, C., Ramirez-Restrepo, M., Gaiteri, C., Myers, A. J., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.02.016 · Cited by 147
Aminophospholipids are signal-transducing TREM2 ligands on apoptotic cells
Shirotani, K., Hori, Y., Yoshizaki, R., Higuchi, E., Colonna, M., Saito, T., Hashimoto, S., Saito, T., Saido, T. C., & Iwata, N. (2019) · Scientific Reports · doi:10.1038/s41598-019-43535-6 · Cited by 116
A cell therapy approach to restore microglial Trem2 function in a mouse model of Alzheimer’s disease
Yoo, Y., Neumayer, G., Shibuya, Y., Mader, M. M.-D., & Wernig, M. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.07.006 · Cited by 109
Microglia and inflammation: conspiracy, controversy or control?
Fernandes, A., Miller-Fleming, L., & Pais, T. F. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1670-8 · Cited by 103
Linnartz, B., Wang, Y., & Neumann, H. (2010) · International Journal of Alzheimer's Disease · doi:10.4061/2010/587463 · Cited by 87
Walter, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.704981 · Cited by 80
Nasu–Hakola disease and primary microglial dysfunction
Bianchin, M. M., Martin, K. C., de Souza, A. C., de Oliveira, M. A., & de Mello Rieder, C. R. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17-c1 · Cited by 69
Woollacott, I. O. C., Nicholas, J. M., Heslegrave, A., Heller, C., Foiani, M. S., Dick, K. M., Russell, L. L., Paterson, R. W., Keshavan, A., Fox, N. C., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0405-8 · Cited by 62
Early-Onset Alzheimer Disease and Candidate Risk Genes Involved in Endolysosomal Transport
Kunkle, B. W., Vardarajan, B. N., Naj, A. C., Whitehead, P. L., Rolati, S., Slifer, S., Carney, R. M., Cuccaro, M. L., Vance, J. M., Gilbert, J. R., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.1518 · Cited by 58
Li, X., Montine, K. S., Keene, C. D., & Montine, T. J. (2015) · The FASEB Journal · doi:10.1096/fj.14-262683 · Cited by 54
Pocock, J., Vasilopoulou, F., Svensson, E., & Cosker, K. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110020 · Cited by 54
Beck, T. N., Nicolas, E., Kopp, M. C., & Golemis, E. A. (2014) · Oncoscience · doi:10.18632/oncoscience.64 · Cited by 50
“TREM2 has been strongly linked to AD and general dementia by several studies [40, 48-50], including the study by Lambert et al.”
BackgroundSWI and phase imaging reveal intracranial calcifications in the P301L mouse model of human tauopathy
Ni, R., Zarb, Y., Kuhn, G. A., Müller, R., Yundung, Y., Nitsch, R. M., Kulic, L., Keller, A., & Klohs, J. (2020) · Magnetic Resonance Materials in Physics, Biology and Medicine · doi:10.1007/s10334-020-00855-3 · Cited by 24
Su, W., Shi, Z., Liu, S., Wang, X., Liu, S., & Ji, Y. (2018) · Annals of Human Genetics · doi:10.1111/ahg.12241 · Cited by 16
TREM2 variants as a possible cause of frontotemporal dementia with distinct neuroimaging features
Samanci, B., Bilgiç, B., Gelişin, Ö., Tepgeç, F., Guven, G., Tüfekçioğlu, Z., Alaylıoğlu, M., Hanagasi, H. A., Gürvit, H., Guerreiro, R., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.14908 · Cited by 14
Metadata
- Authors
- Chouery, E., Delague, V., Bergougnoux, A., Koussa, S., Serre, J.-L., & Mégarbané, A.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2008-09
- Volume
- 29
- Issue
- 9
- Pages
- E194-E204
- ISSN
- 1059-7794 (ISSN-L)
- 1098-1004
- OpenAlex
- W2060689997
- Cited by
- 124
- References
- 7
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.